Education
About Us
Working with TipRanks
Follow Us
Biotest AG (CH:BIO3)
:BIO3
Total Valuation
Biotest has a market cap or net worth of CHF1.35B. The enterprise value is CHF1.62B.
Market CapCHF1.35B
Enterprise ValueCHF1.62B
Share Statistics
Biotest has 19,785,727 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,785,727
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biotest’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 4.18%.
Return on Equity (ROE)0.05
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)4.18%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee325.94K
Profits Per Employee11.85K
Employee Count2,228
Asset Turnover0.51
Inventory Turnover1.05
Valuation Ratios
The current PE Ratio of Biotest is 38.05. Biotest’s PEG ratio is -0.49.
PE Ratio38.05
PS Ratio1.98
PB Ratio1.89
Price to Fair Value1.89
Price to FCF31.19
Price to Operating Cash Flow16.49
PEG Ratio-0.49
Income Statement
In the last 12 months, Biotest had revenue of 726.20M and earned 26.40M in profits. Earnings per share was 0.71.
Revenue726.20M
Gross Profit223.80M
Operating Income94.50M
Pretax Income46.50M
Net Income26.40M
EBITDA120.40M
Earnings Per Share (EPS)0.71
Cash Flow
In the last 12 months, operating cash flow was 60.90M and capital expenditures 0.00, giving a free cash flow of 32.20M billion.
Operating Cash Flow60.90M
Free Cash Flow32.20M
Free Cash Flow per Share1.63
Dividends & Yields
Biotest pays an annual dividend of CHF0.073, resulting in a dividend yield of 0.26%
Dividend Per ShareCHF0.073
Dividend Yield0.26%
Payout Ratio11.68%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.00
52-Week Price Change0.32%
50-Day Moving Average24.40
200-Day Moving Average24.40
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
Biotest upcoming earnings date is May 12, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend DateMay 08, 2024
Financial Position
Biotest as a current ratio of 5.06, with Debt / Equity ratio of 112.53%
Current Ratio5.06
Quick Ratio2.06
Debt to Market Cap0.54
Net Debt to EBITDA4.06
Interest Coverage Ratio2.84
Taxes
In the past 12 months, Biotest has paid 20.20M in taxes.
Income Tax20.20M
Effective Tax Rate0.43
Enterprise Valuation
Biotest EV to EBITDA ratio is 12.41, with an EV/FCF ratio of 46.39.
EV to Sales2.06
EV to EBITDA12.41
EV to Free Cash Flow46.39
EV to Operating Cash Flow24.53
Balance Sheet
Biotest has CHF119.50M in cash and marketable securities with €597.20M in debt, giving a net cash position of CHF477.70M billion.
Cash & Marketable SecuritiesCHF119.50M
Total Debt€597.20M
Net CashCHF477.70M
Net Cash Per ShareCHF24.14
Tangible Book Value Per ShareCHF13.82
Margins
Gross margin is 30.82%, with operating margin of 13.01%, and net profit margin of 3.64%.
Gross Margin30.82%
Operating Margin13.01%
Pretax Margin6.40%
Net Profit Margin3.64%
EBITDA Margin16.58%
EBIT Margin10.99%
Analyst Forecast
The average price target for Biotest is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―